
Tags: B. P. Singh, Bhishma Narain Singh, biotechnology, Business/Finance, Commissioner, drug discovery, europe, Governor, Health/Medical/Pharmaceuticals, India, Japan, Kellogg Company, Managing Director, National Biotech Committee, New Delhi, New York City, NorthWestern Corporation, Northwestern University, pharmaceutical, research services, School of Management, Sikkim, State University, Swapan Bhattacharya, Tamil Nadu, Technology/Internet, The Chatterjee Group, United States
New pharmacovigilance products launched
TAKE Solutions Ltd, a leading technology-enabled business solutions provider in collaboration with BaseCon A/S, a Danish Phamacovigilance products company, is launching a new range of Pharmacovigilance solutions for the Asia Pacific pharmaceutical companies.
Quest Diagnostics’ Laboratory in India Accredited by Leading Laboratory Accrediting Organizations
Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services, today announced that its wholly-owned subsidiary Quest Diagnostics India Pvt. Ltd. has received certificates of accreditation from the College of American Pathologists (CAP), a leading international laboratory accrediting organization, and the National Accreditation Board for Testing and Calibration Laboratories (NABL), the sole government-authorized laboratory accreditation body in India, for its diagnostic and clinical trials laboratory in Gurgaon, India.
Healthcare to attract USD 500 mn PE funding in 3 yrs
The country’s healthcare segment is likely to attract private equity funding to the tune of USD 500 million in the next three years.
Clinical trial insurance comes to the aid of pharma cos
Clinical trial insurance products are now available in India and are being provided by lots of general insurers, including Bajaj Allianz, ICICI Lombard, Tata AIG, Oriental Insurance and New India Assurance, among others.
Emerging trends in Electronic Data Capture : Callum Bir, Director, Life Sciences, Global Industry Business Unit, ORACLE Corporation, Asia Pacific & Japan
[This article was published in the August 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
Increasingly clinical trials are coming under the regulatory lense because of lack of necessary accounting of the patient and drug effects information. The following article takes a look at the new trends in electronic data capture that help track the data better.
Latest in blood glucose meter from Arkray Piramal Medical
Arkray Piramal Medical Pvt Ltd, a Joint Venture between Arkray Inc, Japan and Nicholas Piramal India Ltd a leading pharmaceutical company in India, recently released Glucocard 01, a unique and patented combination of a Ruthenium Based Mediator and Thin film carbon coated electrodes which makes the strips free from temperature and humidity interference thus ensuring accurate and precise results.
NEWS REVIEW – BUSINESS
[This article was published in the May 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
Business News
Changes in pharma CFOs roles: Ernst & Young survey
A latest Ernst & Young survey of Chief financial officers (CFOs) in the Indian pharmaceutical sector underscores important changes in the role of the CFO and the finance function in driving the success of pharmaceutical companies. Respondents of the India CFO survey envisaged a change in their responsibilities, with an increased focus on serving as business partners and managing growth.
NHS urged to work alongwith pharma industry
New guidelines, issued by the Department of Health, call for more partnerships between the NHS and drug companies, stressing they should be “of mutual benefit with the principal beneficiary being the patient”.
GoI and World Bank group to rid health sector projects of corruption
The Government of India and the World Bank Group have joined forces to fight fraud and corruption and systemic deficiencies in India
NEWS REVIEW – INDIA
[This article was published in the January 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
News
Ranbaxy may dilute 60% in new R&D unit
Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.